EUVIMEDEUVIMED entdecken
Crossref

Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021

Maria Abbattista, Alessandro Ciavarella, Declan Noone, Flora Peyvandi

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.01.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Maria Abbattista und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, UOC Medicina Generale, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Ital…. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Thrombosis, Hemostatics. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Safety concerns for an increased risk of thrombotic complications in patients with hemophilia A have been pointed out, particularly during nonreplacement treatment with emicizumab and concomitant bypassing agents. Surveillance with the Roche Global Database reporting adverse events for emicizumab has been discontinued on May 2021. OBJECTIVES: The objective of this study was to evaluate the reporting rate of hemorrhagic and thrombotic adverse drug reactions (ADRs) associated with nonreplacement (emicizumab) and replacement extended half-life (EHL) factor VIII (FVIII) products as retrieved from the EudraVigilance database. METHODS: Total ADR reported during treatment with emicizumab or EHL FVIII products from January 1 to December 31, 2021, were collected. The proportional reporting ratio and the reporting odds ratio (ROR) with their 95% CIs were calculated to express the hemorrhagic and thrombotic ADR reporting frequency ratio between emicizumab and EHL FVIII products. RESULTS: Overall, 406 and 376 ADRs were reported for emicizumab and for EHL FVIII products, respectively. Hemorrhagic and thrombotic ADRs were 232 and 24 for emicizumab and 275 and 9 for the EHL FVIII products. Approximately 25% of thrombotic ADRs were reported concomitantly with eptacog alfa. ROR of 0.49 (95% CI, 0.36-0.66) for hemorrhagic and of 2.56 (95% CI, 1.18-5.59) for thrombotic ADRs were obtained for emicizumab compared with EHL FVIII products. CONCLUSION: The analysis of 2021 EudraVigilance reports shows a lower reporting rate of hemorrhagic ADR vs a higher reporting rate of thrombotic ADR for emicizumab than for EHL FVIII products. These signals stress the importance of monitoring novel drugs in hemophilia, particularly when administered in association with bypassing agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificThrombosisHemostaticsHumansFactor VIIIHalf-LifeHemorrhageAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

drug monitoringhemophiliahemorrhagic disorderspharmacovigilancevascular diseases

Substanzen

Factor VIIIAntibodies, BispecificHemostaticsemicizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, UOC Medicina Generale, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. Electronic address: https://twitter.com/AbbattistaMaria.
  • Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
  • European Haemophilia Consortium, Brussels, Belgium.
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, UOC Medicina Generale, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli…

Förderung

  • Ministero della Salute

Zitieren

APA

Abbattista, M., Ciavarella, A., Noone, D., & Peyvandi, F. (2023). Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.01.010

Vancouver

Abbattista M, Ciavarella A, Noone D, Peyvandi F. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.01.010

BibTeX
@article{Abbattista2023,
  author = {Abbattista, Maria and Ciavarella, Alessandro and Noone, Declan and Peyvandi, Flora},
  title = {Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.01.010}
}
Kostenlos starten →